Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C.
نویسندگان
چکیده
The aims of this study were to compare chronic hepatitis B (CHB) patients with genotypes B and C for the probability of HBeAg seroconversion, hepatitis activity, and viral replication before and after HBeAg seroconversion and to compare the prevalence of core promoter and precore mutations. A total of 180 asymptomatic Chinese patients with CHB were monitored for a median of 53.8 months, and 38 patients with cirrhosis-related complications were studied. Hepatitis B virus (HBV) DNA levels were measured in 16 patients with HBeAg seroconversion at 3 months before, during, and 3 months after HBeAg seroconversion and in all patients at the last follow-up. Hepatitis B genotypes and core promoter and precore mutations were determined. Compared to patients with genotype C (n = 109), patients with subtype Ba (n = 69) had a higher rate of anti-HBe positivity on presentation (P = 0.05). HBeAg-positive patients with subtype Ba had a higher cumulative rate of HBeAg seroconversion than patients with genotype C (P = 0.02). However, there were no differences between the two groups with regard to the median HBV DNA levels before, during, and after HBeAg seroconversion; the probability of having persistently normal or elevated aminotransferase levels; and the median HBV DNA levels and liver biochemistry at the last follow-up. There was no difference in the prevalence of genotypes and core promoter and precore mutations between patients with and without cirrhosis-related complications. Though patients with subtype Ba had earlier HBeAg seroconversion, the liver biochemistry, HBV DNA levels in different phases of the disease, and the probability of development of cirrhosis-related complications were the same with genotypes Ba and C.
منابع مشابه
THE EFFICACY AND SA FETY OF INTERFERON ALFA FOR THE TREATMENT OF CHRONIC HEPATITIS B INFECTED SUBJECTS IN IRAN
This preliminary study was designed to evaluate the effects of Heberon Alfa for the treatment of chronic hepatitis B infected subjects in Iran. A single center, open label, single treatment prospective study of Interferon Alfa (Heberon Alfa), 5 million units every other day for a period of 4 months, was performed between 1996 to 1998. A total number of 30 patients with histologically docume...
متن کاملDistribution of Genotypes of B and C Hepatitis Viruses in Guilan Province
Today, chronic viral hepatitis is considered as a public health problem in the world. Totally, 5% of the world population, especially in Asia and Africa suffer from this problem. The prevalence of acute hepatitis in America is 0.1-0.2 percent, 50% of those with hepatitis C (HCV) and 5-10% of them with hepatitis B (HCV) develop chronic hepatitis. Determining HBV and HCV genotypes is important to...
متن کاملDetection of SENV Virus in Healthy, Hepatitis B- and Hepatitis C-Infected Individuals in Yazd Province, Iran
Background: SEN virus (SENV) is the latest virus proposed as a cause of unknown hepatitis cases. Among nine detected genotypes of the virus, genotypes D and H are more frequent in hepatitis cases of unknown origin. The aim of this study was to determine the frequency of SENV-D and SENV-H genotypes in the sera of healthy individuals and hepatitis B and C patients. Methods: Totally, 200 serum sam...
متن کاملAnalysis of Precore/Core Covariances Associated with Viral Kinetics and Genotypes in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients
Hepatitis B virus (HBV) is one of the most common DNA viruses that can cause aggressive hepatitis, cirrhosis and hepatocellular carcinoma. Although many people are persistently infected with HBV, the kinetics in serum levels of viral loads and the host immune responses vary from person to person. HBV precore/core open reading frame (ORF) encoding proteins, hepatitis B e antigen (HBeAg) and core...
متن کاملبررسی اثر آلفا انترفرون در 16 بیمار مبتلا به هپاتیت مزمن ویروسی
Alpha-interferon therapy has been approved for treatment of chronic hepatitis C and B. Candidates for treatment are patients with well-compensated liver disease and histologic evidences of chronic hepatitis who have demonstrated abnormal aminotransferase levels for more than 6 months. From 30 patients with chronic hepatitis with diseases prolonged more than 6 months, we selected only 16 patient...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of clinical microbiology
دوره 42 11 شماره
صفحات -
تاریخ انتشار 2004